*The CDC also recommends hepatitis B vaccination for adults aged ≥60 with risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.†Estimate based on World Health Organization data from 2019. CDC, Centers for Disease Control and Prevention.

INDICATION

HEPLISAV-B is indicated for the prevention of infection caused by the hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

If you have a history of severe allergic reaction after a previous dose of any hepatitis B vaccine, or to any ingredient of HEPLISAV-B, including yeast, do not take HEPLISAV-B.

HEPLISAV-B must be given by a medical professional, who will monitor you afterwards to check for allergic reaction.

If you are immunocompromised, or receiving immunosuppressant therapy, you may have less of an immune response to HEPLISAV-B.

Some people have hepatitis B infection without being aware of it or showing any symptoms. If you already have hepatitis B present in your body, HEPLISAV-B may not prevent hepatitis B infection.

The most common side effects reported by patients within 7 days of vaccination with HEPLISAV-B were pain at the site of injection (23%-39%), tiredness (11%-17%), and headache (8%-17%)

.Please see full Prescribing Information.

© 2022 Dynavax Technologies Corporation. All rights reserved. US-22-00-00417